Loading
Life sciences · Journal article
The Lancet Regional Health - Americas · November 5, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Despite the scientific and technical capacity for precision oncology in North America (Canada, the United States, and Mexico), its implementation is deeply uneven across the region. Our narrative synthesis of precision oncology implementation found that delivery consistently fails at four operational steps: biomarker testing, molecular interpretation, reimbursement, and access to matched standard-of-care therapy or clinical trial. These failures arise along disparity axes that differ by country but converge on a single outcome: patients whose cancers harbor actionable biomarkers do not receive precision oncology-based care. We conclude that precision oncology must be treated as essential cancer-care infrastructure rather than an optional research-based service and propose a tri-national implementation agenda. Acting now is particularly urgent given the rapid emergence of artificial intelligence (AI) models trained on precision oncology-derived datasets, which risk entrenching existing inequities into clinical decision-making before implementation reform can catch up.